Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The congenital myopathies are a clinically, genetically and pathologically heterogeneous group of muscle disorders defined in many patients by the presence of particular histopathological features. They emerged as a group of disorders with the wider application of histochemistry and electron microscopy in the 1950s and 1960s, when abnormal structural defects were identified in association with a particular phenotype, before any molecular causes were known. Historically, the recognition of this group of disorders probably dates from the description of ‘a new congenital non-progressive myopathy’ by , later named central core disease (see below), and the subsequent demonstration of the striking histochemical picture by . Presentation of congenital myopathies is often at birth or in early childhood, but some cases with a structural defect may have adult onset and are thus not strictly ‘congenital’. Some of these are part of a clinical spectra, whereas others are different entities sharing pathological features with congenital cases. Clinically, the congenital myopathies often fall into the ‘floppy infant’ category with a variable degree of hypotonia ( ). Muscle weakness is often, but not always, relatively non-progressive, particularly in early decades, but diaphragmatic weakness and respiratory insufficiency may be disproportionate. Structural abnormalities in the central nervous system or peripheral nerves are absent, and congenital myopathies are therefore regarded as primary myopathies.
Advances in molecular analysis and the wide application of next-generation sequencing and gene panels have led to the identification of several causative genes and a wider appreciation of the clinical phenotype and morphological features associated with them ( ). Some of the more common forms are relatively well-defined disorders with a well-recognized pathological feature, while others are very rare and may be based on very few isolated patients. In these, it is not yet clear if all are distinct genetic entities. The genes responsible for several congenital myopathies described before the molecular era have now been identified, and it is apparent that they often form part of a clinicopathological spectrum rather than being distinct disease entities. For example, the presence of cap-like areas is associated with several genes (see below); zebra body myopathy is caused by a mutation in the ACTA1 gene encoding skeletal actin, sarcotubular myopathy by the gene for TRIM32, spheroid myopathy by the MYOT gene encoding myotilin and reducing body myopathy by the gene for four-and-half LIM domain 1 ( FHL1 ) ( ). All of these genes are also associated with other phenotypes. Few of the pathological features are specific for a particular disorder. It is now apparent that there is considerable pathological overlap between the various congenital myopathies, and the pathological distinction between them is not always clear. Mutations in different genes can lead to the presence of the same histopathological feature, sometimes as a result of functional association of the gene products, and mutations in the same gene can give rise to a variable clinical and pathological phenotype, some of which may be classified in other groups of disorders ( Tables 15.1 and 15.2 ). This has challenged the traditional classification of several disorders. The pathogenic mechanisms underlying the presence of the structural abnormalities are not fully understood, although various pathways have been considered ( ).
RODS ACTA1, NEB, TPM2, TPM3, TNNT1, CFL2, KBTBD13, KLHKL40, KLHL41, LMOD3, MYPN, TNNT3, MYOB18, TTN, RYR1, RYR3, EXOSC3, PPA2 CORES OF VARYING SIZE RYR1, SELENON (formerly SEPN1), ACTA1, KBTBD13, TTN, MYH7, CFL2, MYH2, ACTN2, MEGF10 and others CENTRAL NUCLEI
RODS AND CORES |
Gene | Inheritance | Protein | |
---|---|---|---|
Nemaline Myopathies | |||
ACTA1 | AD (AR) | Skeletal α-actin | |
NEB | AR | Nebulin | |
TPM3 | AD | α-Tropomyosin, slow | |
TPM2 | AD | β-Tropomyosin | |
TNNT1 | AR | Slow troponin T1 | |
TNNT3 | AR | Fast troponin T3 | |
CFL2 | AR | Cofilin-2 | |
KBTBD13 | AD | Kelch repeat- and btb/poz domain-containing protein 13 | |
KLHL40 | AR | Kelch-like family member 40 | |
KLHL41 | AR | Kelch-like family member 41 | |
LMOD3 | AR | Leiomodin 3 | |
MYOB18 ∗ | AR | Myosin XVIIIB | |
Other Myopathies with Rods | |||
Rods and cores | RYR1 | AR or AD | Ryanodine receptor 1 |
ACTA1 | AD (AR) | Skeletal α-actin | |
NEB | AR | Nebulin | |
Rods and caps | TPM2 | AD | β-Tropomyosin |
TPM3 | AD (AR) | α-Tropomyosin, slow | |
ACTA1 | AD | Skeletal α-actin | |
TTN | AR | Titin | |
Congenital Myopathies with Cores | |||
Central core disease | RYR1 | AD or AR | Ryanodine receptor 1 |
Multi-minicore disease | SELENON (SEPN1) | AR | Selenoprotein N |
Congenital myopathy with or without cardiomyopathy | TTN | AR | Titin |
Central Nuclear Myopathies | |||
Myotubular myopathy | MTM1 | XLR | Myotubularin |
Centronuclear myopathy | DNM2 | AD (AR) | Dynamin-2 |
BIN1 | AR | Amphiphysin-2 | |
RYR1 | AD, AR | Ryanodine receptor 1 | |
SPEG | AR | SPEG complex locus | |
Centronuclear myopathy with cores | CCDC78 | AD | Coiled-coil domain-containing protein 78 |
Congenital myopathy with or without cardiomyopathy | TTN | AR | Titin |
Surplus Protein Congenital Myopathies | |||
Actin aggregation | ACTA1 CFL2 |
AD AR |
Skeletal α-actin Cofilin-2 |
Zebra body myopathy | ACTA1 | ?AD | Skeletal α-actin |
Myosin storage myopathy | MYH7 | AD | Slow/β-cardiac myosin heavy chain |
Myopathies with caps | TPM2 | AD | β-Tropomyosin |
TPM3 | AD | α-Tropomyosin, slow | |
ACTA1 | AD | Skeletal α-actin | |
TTN | AR | Titin | |
Reducing body myopathy ♦ | FHL1 | XLD | Four-and-half LIM domain-1 protein |
Spheroid body myopathy ♦ | MYOT | AD | Myotilin |
FLNC | AD | Filamin C | |
Myopathies with Abnormal Type 2A Fibres | |||
Myopathy with congenital joint contractures and ophthalmoplegia | MYH2 | AD | Myosin heavy chain IIa |
Myopathy with absent/abnormal type 2A fibres and ophthalmoplegia | MYH2 | AR | Myosin heavy chain Iia |
Congenital Fibre Type Disproportion | |||
ACTA1 | AD | Skeletal α-actin | |
SELENON | AR | Selenoprotein N1 | |
TPM3 | AD | α-Tropomyosin, slow | |
TPM2 | AD | ||
RYR1 | AD or AR | Ryanodine receptor | |
MYH7 | AD | Myosin heavy chain 7 | |
HACD1 (PTPLA) | AR | 3-Hydroxyacyl-CoA dehydratase 1 |
∗ Mutations in MYOD18 have only been identified in a few patients with a complex phenotype that is not typical of nemaline myopathy.
♦ These disorders were historically classified as congenital myopathies but now are usually grouped with other disorders (see text).
Inheritance of congenital myopathies may be autosomal recessive, autosomal dominant or X-linked, and there is a high incidence of de novo dominant mutations.
In this chapter we describe the pathology of the more common congenital myopathies with particular structural features that a pathologist is likely to encounter. In addition, we also describe some of the more recently identified entities. We have deliberately steered away from a molecular categorization, as it is the pathology in association with the clinical phenotype that usually leads to identification of the causative gene defect. Molecular advances, however, have led to greater knowledge of the range of morphological features that can occur in association with a broad range of clinical phenotypes and molecular defects. We include in this chapter a group of disorders caused by mutations in genes that encode sarcomeric proteins but that do not always show a particular structural pathological feature. Some of these disorders present with congenital arthrogryposis, a clinical feature of several syndromes and not a diagnostic feature, and a myopathic aetiology, and muscle weakness may not be as apparent as in cases with structural abnormalities. Some of the same genes, however, can result in a structural defect or present in adulthood, but the disorder is still classified with congenital myopathies (see Table 15.2 ), emphasizing the pathological and genetic overlap. The most common congenital myopathies are the core myopathies (central core disease and multi-minicore myopathy), nemaline myopathies, and myotubular and centronuclear myopathies (see below; see Table 15.2 ) ( ), but pathological overlap is now recognized. Additional rare disorders characterized by other morphological features are listed in Table 15.3 .
Gene | Inheritance | Protein | Function of Protein |
---|---|---|---|
CACNAIS ∗ | AD or AR | Calcium voltage-gated channel subunit alpha1 S | Excitation-coupling |
SCN4A ∗∗ | AR | Sodium voltage-gated channel alpha subunit 4 | Ion-channel |
STAC3 | AR | SH3 and cysteine-rich domains 3 | Excitation-coupling |
TRDN | AR | Triadin | Excitation-coupling |
ZAK | AR | Mitogen-activated protein triple kinase | Signal transduction |
MEGF10 | AR | Multiple epidermal growth factor (EGF)-like domains 10 | Satellite cell function |
PYROXD1 | AR | Pyridine nucleotide-disulphide oxidoreductase domain 1 | Regulation of redox potentials |
MYMK (TMEM8C) | AR | Myomaker | Transmembrane protein involved in fusion of myoblasts |
MYL1 | AR | Fast myosin light chain 1 | Alkali light chain involved with muscle contraction |
TRIP4 | AR | Activating signal cointegrator-1 | Transcription coactivator |
UNC45B | AD or AR | Uncordinated mutant number-45 myosin chaparone B | Myosin assembly and lens development |
∗ See Chapter 20 for involvement in other disorders.
∗∗ See Chapter 21 for involvement in other disorders.
In this section we discuss the disorders that have traditionally been classified as ‘congenital myopathies’, core myopathies, nemaline myopathies and centronuclear myopathies, although it is now recognized that there is considerable pathological overlap among them.
The spectrum of clinical features, severity and progression of disease is variable in the different forms of congenital myopathy ( ). Hypotonia is usually present at birth or early infancy, although rare cases with hypertonia and a ‘stiff’ phenotype have been reported ( ). Several additional clinical features also distinguish the various congenital myopathies. Muscle weakness may be predominantly proximal and of limb-girdle distribution, thus resembling muscular dystrophy or mild forms of spinal muscular atrophy, or it may be more generalized. In some individuals, weakness may show marked involvement of the axial muscles and the face, and a few may show prominent distal involvement. A long ‘myopathic’ face is a common feature, particularly in nemaline myopathy, and extraocular involvement occurs in some forms. Structural abnormalities of the central nervous system or peripheral nerves do not usually occur and intelligence is usually normal. Although generally non-progressive, diaphragmatic involvement may be disproportionate to overall muscle weakness, in particular in some cases of nemaline myopathy and multi-minicore disease (see also below MEGF10 ).
Arthrogryposis may be a feature in some severe cases of congenital myopathies ( ), as well as being a symptom in some disorders without structural defects (see below). Lordosis, spinal rigidity, scoliosis and joint laxity are common, and hip dislocation is a particular feature of RYR1- related core disease, although all of these can also be clinical features of other disorders: for example, Ullrich congenital muscular dystrophy.
Myasthenic-like symptoms can also be present in some cases with a congenital myopathy, with defects in various genes including TPM2 , TPM3, BIN1 , DNM2, MTM1 and RYR1 (see Ch. 21 and ). It is important to identify these individuals, as they often respond well to therapy.
Serum creatine kinase (CK) levels are usually normal and electrophysiological studies rarely help in diagnosis but can be of use in patients with myasthenic-like symptoms. Ultrasound imaging often shows increased echo and may reveal differential involvement of muscles. This can be helpful in deciding which muscle to sample. The differential involvement of muscles is clearly seen with magnetic resonance imaging (MRI), and data indicate that particular patterns of selective involvement of thigh and lower leg muscles are associated with mutations in certain genes and are helpful in directing molecular analysis ( ). Muscle biopsy, with detailed histochemical studies, supplemented by immunohistochemistry and electron microscopy, is essential for the diagnosis of congenital myopathies for directing and for interpreting molecular analysis.
Atrophy or hypotrophy (small fibres that have not attained their normal diameter) of type 1 fibres is seen in several congenital myopathies, and may appear as fibre type disproportion (see below). There is often a marked predominance or uniformity of type 1 fibres, but the intensity of staining is often less than that seen in normal muscle and intermediate between type 1 and 2 fibres. The involvement of type 1 fibres, however, is not universal and in some cases it involves type 2 fibres (e.g. some cases of nemaline myopathy, see below). Antibodies to myosin isoforms confirm the slow phenotype of most fibres but, again, the intensity of labelling may be less than in normal muscle. In addition, co-expression of developmental isoforms and slow and/or fast myosin may occur in very young patients. Necrosis and regeneration are not typical features of congenital myopathies. Fibrosis is also rare but can occur (see section on core myopathies and nemaline myopathies). Scattered, very small fibres (< 5 μm) containing fetal myosin (sometimes colloquially referred to as ‘pinpricks’), however, are often seen (see Figs. 6.25 and 6.26), but the origin of these is not clear, nor whether they represent attempts at regeneration. Centrally placed nuclei are a particular feature of myotubular and centronuclear myopathies (see below), and they are also common in association with mutations in the RYR1 and TTN genes (see below). Multiple internal nuclei are a particular feature of patients with mutations in the PYRODX1 gene (see below).
Areas devoid of oxidative enzyme stains are the characteristic pathological feature of the ‘core myopathies’. However, there is considerable variability and overlap in the clinical, pathological features and genotypes that can make differential diagnosis difficult. We therefore find it useful to refer to this group of disorders with clinical features of a congenital myopathy collectively as ‘core myopathies’. We discuss, however, the two historical categories of central core disease and multi-minicore myopathy as these are well established terms but also discuss the expanding clinical, pathological features of the genotypes associated with cores of varying types.
Historically, the identification of ‘central core disease’ dates back to when described a ‘new congenital non-progressive myopathy’ affecting five patients in three generations of the same family, ranging in age from 2 to 65 years. The main clinical features were hypotonia and delay in motor milestones in infancy, and a mild non-progressive weakness, affecting proximal muscles more than distal, and the legs more than the arms. The muscle was characterized by amorphous-looking central areas within the muscle fibres, and subsequently suggested the name ‘central core disease’. A second case documented by was studied histochemically ( ) and the classical histochemical features noted, in particular well-delineated areas that ran down a considerable length of the fibres that were devoid of oxidative enzyme stain and phosphorylase. These core areas were not necessarily central and many fibres had multiple large cores. In addition, the normal fibre typing was lost and the fibres had a uniform appearance of only type 1 fibres. Electron microscopy showed a virtual absence of mitochondria and sarcoplasmic reticulum in the core region, a marked reduction in the intermyofibrillar space and an irregular pattern (streaming) of the Z lines ( ).
Since these early reports there have been many additional cases with this phenotype associated with prominent core lesions. With the advent of molecular genetics there has been a greater understanding of the clinical and pathological phenotype of central core disease as well as a greater understanding of the consequences of the genetic causes ( ).
The inheritance of many cases of central core disease is autosomal dominant, with variable penetrance, several of which are sporadic, de novo dominant cases. An increasing number of cases with recessive inheritance in the RYR1 gene as the cause of central core disease have also been identified. These often have more marked axial weakness, illustrating the overlap with multi-minicore myopathy (see below), and they may have ophthalmoplegia ( ).
Central core disease is one of the most common congenital myopathies ( ). Cases identified prior to the molecular era showed a fairly consistent clinical phenotype, presenting with hypotonia and developmental delay. The phenotype is now known to be wider, and cases with a severe presentation with features of the fetal akinesia sequence have been reported as well as several cases with recessive inheritance ( ). Many of the severely affected infants require ventilation at birth, with progression leading to death in infancy. Other cases, in contrast, may show considerable improvement, and it may be possible to wean the infants off tracheostomy ventilation; one reported child eventually became independently ambulant ( ).
Weakness in most familial cases is pronounced in the hip girdle and in the axial muscle groups and may be associated with muscle wasting. Facial involvement is usually mild and lack of complete eye closure may be the only finding. Orthopaedic complications are common and include congenital dislocation of the hips and scoliosis. Contractures, other than Achilles tendon tightness, are rare, and many affected individuals have marked ligamentous laxity, occasionally associated with patellar instability, illustrating the phenotypic overlap with disorders such as Ullrich congenital muscular dystrophy. Apart from the most severe neonatal cases, and some of those with congenital dislocation of the hips ( ), most patients achieve independent walking. The course of central core disease is often static, or only slowly progressive, even over prolonged periods of time ( ), although there may be progression with age. Primary cardiac involvement is rare and respiratory involvement is usually milder than in other congenital myopathies, except in the severe neonatal cases. Serum CK activity is usually normal or only mildly elevated. A striking feature of central core disease is the differential muscle involvement, which can be shown on muscle ultrasound and, more strikingly, with MRI of muscle which reveals a characteristic pattern of selective involvement, even within the quadriceps, with sparing of the rectus femoris ( ). This is helpful when selecting the site for a muscle biopsy as well as for diagnosis ( ).
The RYR1 gene that is responsible for both dominant and recessive forms of core myopathies is also associated with other phenotypes, including malignant hyperthermia susceptibility, King–Denborough syndrome and exercise intolerance with rhabdomyolysis (see Ch. 21 ; ). As the RYR1 gene is associated with malignant hyperthermia susceptibility, all patients with central core disease are considered at risk and appropriate precautions need to be taken.
Fibre size variation occurs but is often mild. Fibre hypertrophy is common, particularly in adults ( Fig. 15.1 ). When fibre typing is retained, the cores have a predilection for type 1 fibres but fibre type uniformity is common, with most fibres staining as type 1 fibres, with the associated properties of slow fibres (see Fig. 15.1 ). A few fibres may co-express fast myosin and there may be a population of very small fibres (‘pinpricks’ < 5 μm in diameter) with fetal myosin scattered throughout the biopsy (see Fig. 6.26 ). The intensity of stain of the type 1 fibres, however, may not always be as strong as in normal muscle. Classical cores may be central or peripheral, single or multiple, but clearly demarcated cores are not always evident in all cases (see Fig. 15.1 ) and some genetically proven cases only show an appearance of fibre type disproportion ( ) (see below). Very young cases, in particular, may only show type 1 uniformity or predominance, suggesting there is an age-related development of the cores (see Fig. 15.1 ; ). This is well illustrated in a mouse model in which an RYR1 mutation caused an age-related appearance of different size cores and ultimately led to the appearance of nemaline rods ( ). Other cases may show only subtle unevenness in oxidative enzyme stains ( Fig. 15.2 ) or multiple focal areas of disruption of variable size, resembling minicores, making a histopathological distinction difficult ( ) ( Fig. 15.1 ; see below). Recessive cases, in particular, may show multiple cores rather than prominent central cores ( ). It is important to remember that core formation is a secondary morphological consequence of disturbances in cellular events that may not itself be the reason for the muscle weakness ( ).
In many cases of central core disease, particularly dominantly inherited cases, the cores are of the ‘structured’ type, as they retain a striated myofibrillar pattern and myofibrillar adenosine triphosphatase (ATPase) activity, although myofibrils of the core are often very contracted ( Fig. 15.3 ). The distinction of ‘structured’ versus ‘unstructured’ cores is not of diagnostic value. In ‘unstructured cores’, myofibrillar ATPase activity is lost ( Fig. 15.4 ) and there is severe myofibrillar disruption with pronounced accumulation of smeared Z line material which may account for the red appearance reported with the Gomori trichrome ( ). The cores in recessive cases are often unstructured, and variable in size, affecting many or only a few sarcomeres; or they may even stretch across the width of a fibre ( ). The length of the cores can be variable but in dominantly inherited cases they are long, extending down an appreciable length of a fibre. The area devoid of mitochondria may be more extensive than the apparent ultrastructural myofibrillar disruption. Sarcoplasmic reticulum and T tubules may also be reduced in cores but some tubular structures may be apparent within them. Cores are often delineated by a rim of periodic acid–Schiff (PAS) stain but lack glycogen within them and consequently also lack phosphorylase (see Ch. 4 ). Immunohistochemistry shows that desmin may accumulate at their perimeter or within them ( Fig. 15.5 ), and other proteins that have been shown to accumulate in cores include αB-crystallin, filamin C, small heat-shock proteins, myotilin, RyR1 and DHPR ( ).
Internal nuclei had not been considered a feature of central core disease in studies of early cases but it is now appreciated that they can be an important indicator of central core disease and defects in the RYR1 gene ( Fig. 15.6a, d ). In some cases they may be numerous, and several may be in a central position, resembling a centronuclear myopathy ( ; see below), but cores may not be obvious. Similarly, an increase in connective tissue was not considered a feature of ‘classical’ cases but can occur, and in some samples there may also be extensive adipose tissue (see Fig. 15.6d ; Fig. 15.6e ). In these samples the separation of fascicles of fibres by adipose tissue and fibrous tissue may cause diagnostic confusion with a muscular dystrophy. Some of these samples may show only subtle unevenness of oxidative enzyme stains, while others show large classical cores or multiple small cores (minicores; see Fig. 15.6b, c, f ).
Although cores are the characteristic feature of central core disease caused by mutations in the gene encoding the ryanodine receptor 1 ( RYR1 ), core formation can also occur following tenotomy, following neurogenic atrophy (see Ch. 9 ). Small focal cores (minicores) can be associated with several gene defects, including SELENON (formerly SEPN1 ) and MYH2 (see below) and the ACTA1, MYH7, TTN, CFL2, KBTBD13, ACTN2 and MEGF10 genes, encoding skeletal α-actin, β-myosin heavy-chain, titin, cofilin2, a protein of the Kelch family, α-actinin 2, and multiple epidermal growth factor-like domains 10, respectively (see Table 15.1 and sections below; ). Cores in association with central nuclei have also been identified in association with the CCDC78 gene ( ). Cores can coexist with rods ( Fig. 15.7 ) and be associated with RYR1, ACTA1 and NEB mutations (see below) ( ). If rods are in a focal aggregate this may appear as a core, as there are no mitochondria and thus no oxidative enzyme stain. In cases described as ‘core-rod myopathy’ the cores and rods are in separate fibres. In some cases with RYR1 mutations, only a few fibres may show rods ( Fig. 15.8 ; ). The coexistence of rods and cores is likely to be genetically heterogeneous as there are examples of cases where linkage to RYR1 and to the loci of nemaline myopathy (see below) has been excluded.
Central core disease is caused by mutations in the gene for the skeletal muscle ryanodine receptor ( RYR1 ) on chromosome 19q. The same gene is also responsible for malignant hyperthermia susceptibility (although additional loci are also linked to this), King–Denborough syndrome and exercise intolerance associated with rhabdomyolysis. The precise association between central core disease and malignant hyperthermia is not clear but, as pointed out previously, all patients with central core disease are considered at risk and appropriate precautions need to be taken.
The RYR1 gene contains 106 exons and encodes the skeletal muscle ryanodine receptor protein (RyR1), named after the fact that it binds ryanodine. The receptor is a large transmembrane, tetrameric structure of the sarcoplasmic reticulum and is involved in the regulation of cytosolic calcium levels and excitation–contraction coupling. Genotype–phenotype correlations suggest that mutations in the cytoplasmic N-terminal domain and the cytoplasmic central domain mostly result in malignant hyperthermia susceptibility rather than in central core disease, while mutations affecting the C-terminal exons of the gene commonly result in central core disease ( ). Mutations in the C-terminal exons (95–102) often result in the classical central core pathology with large cores and account for approximately 66% of cases. Recessive mutations can occur in any region of the gene and are often associated with multiple minicores ( ). The majority of mutations in the RYR1 gene are missense mutations, although deletions have also been detected ( ).
The large size of the RYR1 gene makes molecular analysis laborious, although there are ‘hot spots’ for mutations that can help direct analysis ( ). The phenotypic and histopathological variability associated with the RYR1 gene is broad, but the use of gene panels and next-generation sequencing has considerably assisted diagnosis and the identification of mutations. There are, however, many polymorphisms and variants of unknown significance in this large gene. Studies of the RyR1 protein by immunoblot analysis can reveal a reduction and help to determine if a change is pathogenic ( ). Another complicating factor in the RYR1 gene is that tissue-specific epigenetic silencing of the normal allele, resulting in expression of only the mutant allele, may occur ( ). Although further studies of the cases reported by Zhou et al revealed an additional mutation in four out of the five cases, casting doubt on the proposal of epigenetic silencing, gene silencing could not be excluded in the fifth ( ). This study of Zhou et al highlights the limitation of only studying genomic DNA and the contribution of genetic modifiers is now appreciated ( ).
In summary, the clinical and histopathological spectra associated with mutations in the RYR1 gene are wide. The use of the term ‘central core’ disease for all of them may be confusing, as some biopsies do not show classical cores. They are linked, however, by common clinical features, and similar patterns of muscle involvement, indicating a spectrum of one disorder. For the histopathologist, difficulties in diagnosis may arise if the classical features are not present and because of the histopathological overlap between the various congenital myopathies. In our experience mutations in the RYR1 gene are particularly common and digenic problems should therefore sometimes be considered, particularly if the phenotype is atypical ( ). The pathology associated with one gene can be masked by that of the other ( ). The features that should alert the pathologist to defects in the RYR1 gene are central nuclei, any unevenness in oxidative enzyme stain, be it marked or subtle, and type 1 fibre uniformity or marked predominance. When fibre type disproportion in the absence of cores is present, the RYR1 gene also has to be considered. The coexistence of cores and rods in any fibres also suggests an RYR1 mutation should be considered but can also occur in association with other gene defects such as nebulin and skeletal α-actin (see below).
In documented two unrelated children with a benign congenital non-progressive myopathy associated with multifocal areas of degeneration in the muscle fibres and suggested the name ‘multicore disease’. Since the original description, there have been several reports of cases with a wide range of clinical phenotypes associated with similar histopathological features. The defining histopathological feature is multiple small areas devoid of oxidative enzymes which lack mitochondria and, ultrastructurally, show focal disruption of the sarcomeric pattern.
The clinical features of cases with multicores are variable and multiple cores can occur in association with mutations in several genes (see sections above and below), and to some extent are a non-specific pathological feature that can be seen in many disorders. Correlation with clinical phenotype is thus essential. Multi-minicore myopathy is not a single entity and is a name that has been given to several myopathies in which a muscle biopsy shows multifocal areas devoid of oxidative enzyme stains. They could therefore be described more accurately as ‘myopathies with multi-minicores’.
The defining feature is multiple focal areas of myofibrillar disruption that lack mitochondria. These can be demonstrated with the oxidative enzyme stains reduced nicotinamide adenine dinucleotide-tetrazolium reductase (NADH-TR), cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) and may appear as punctate or more diffuse areas devoid of stain ( Fig. 15.9 ). The NADH-TR reaction is less specific for absent mitochondria, as unevenness of stain can also relate to general disruption of ultrastructure and loss of myofibrils. Assessment with COX or SDH should therefore also be performed. In some cases, the unevenness of oxidative stain may be subtle and difficult to define as abnormal. Ultrastructurally, minicores show a variable degree of focal disruption of myofibrils that affects only a few sarcomeres. In some fibres, only misalignment of the myofibrils compared with surrounding myofibrils may be seen; in others, focal Z line streaming may occur, while in others the normal sarcomeric structure may be completely disrupted in a varying number of sarcomeres (see Ch. 5 ). Small focal areas adjacent to capillaries resembling minicores are a common non-specific feature. The consistent feature of minicores, however, is the absence of mitochondria, which may extend over a greater area than the disrupted myofibrils. Detailed ultrastructural studies are needed to observe this.
As in central core disease, immunocytochemistry can be helpful in observing the lesions, and proteins such as desmin, myotilin and filamin C can accumulate within them ( ), but there is no specific histopathological method to distinguish the molecular origin of any cores. In contrast to some central cores, minicores are not usually delineated by desmin. Immunolabelling of myosin isoforms can be used to assess the proportion of fast and slow fibres and there are usually only a few, or no, fibres containing fetal myosin in cases with mutations in the SELENON gene (previously known as SEPN1 ) (see below).
A common phenotype associated with minicores shows marked axial weakness with spinal rigidity, scoliosis, torticollis and respiratory involvement that is often disproportionate to the overall muscle weakness. Patients are clinically similar to cases with the rigid spine syndrome and congenital muscular dystrophy (RSMD1), and the two disorders are considered allelic ( ). Both are caused by recessive mutations in the gene for selenoprotein N encoded by the gene now known as SELENON , and the spectrum also includes cases with Mallory bodies (Ferreiro et al 2004; see Chapter 12, Chapter 5 ).
Multiple minicores can also be seen in RYR1 -related myopathy with similar proximal and axial weakness and also showing partial or complete external ophthalmoplegia. Mutations (usually recessively inherited) in the RYR1 gene in these patients form part of the spectrum of changes associated with the RYR1 gene (see above; ), emphasizing the overlap in the core myopathies. Primary cardiac malfunction is not a typical feature of these groups of patients with multiple minicores, and many of the cases reported in the literature showing minicores with cardiac involvement are molecularly unsolved and probably heterogeneous. Some cases, however, have been shown to have a mutation in the MYH7 gene ( ) or the gene encoding titin ( ). Recently, two patients were identified with mutations in the ACTN2 gene encoding α-actinin 2 and biopsies showed unusual large multiple peripheral structured cores ( ); neither case, however, presented with hypotonia
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here